Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001178913-25-002894
Filing Date
2025-08-14
Accepted
2025-08-14 08:01:04
Documents
48
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 6-K zk2533584.htm   iXBRL 6-K 19821
2 EXHIBIT 99.1 exhibit_99-1.htm   iXBRL EX-99.1 566140
3 EXHIBIT 99.2 exhibit_99-2.htm EX-99.2 111205
4 EXHIBIT 99.3 exhibit_99-3.htm EX-99.3 149154
10 GRAPHIC image00002.jpg GRAPHIC 26844
  Complete submission text file 0001178913-25-002894.txt   3282329

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cmmb-20250630.xsd EX-101.SCH 40901
6 XBRL CALCULATION FILE cmmb-20250630_cal.xml EX-101.CAL 30535
7 XBRL DEFINITION FILE cmmb-20250630_def.xml EX-101.DEF 46513
8 XBRL LABEL FILE cmmb-20250630_lab.xml EX-101.LAB 374623
9 XBRL PRESENTATION FILE cmmb-20250630_pre.xml EX-101.PRE 136471
50 EXTRACTED XBRL INSTANCE DOCUMENT zk2533584_htm.xml XML 385769
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38807 | Film No.: 251214451
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)